 |
|
| REAL R & D OPTIONS
| |
| | |
|
|
To order this title, and for more information, click here
Edited By
Dean Paxson, Professor of Finance, Manchester Business School.
Included in series
Quantitative Finance,
Description
Real R&D options are among the earliest modelled real options, with now ten primary practical uses: general R&D planning, planning R&D
in stages, evaluating test information, new product development timing, operations, abandonment, risk sharing, market funding, industry
strategy and regulation.
This book was partly motivated by requests to identify and develop real option models for R&D in telecommunications,
petroleum technology and biotechnology. Nine new models cover information and implementation costs, analytical solutions for mean reverting,
or fat tailed revenues, endogenous learning and exogenous and experiential shocks, American sequential options, and innovator advantages.
Four new applications include forward start development options, exploration options, innovation with information costs, and innovator's
real values with changing market share.
R&D directors and researchers will find several uses for these models:
general R&D planning
evaluating test information
new product development timing
risk sharing
industry strategy and regulation
Audience
Corporate financiers; CIOs using 'Real Options' in business valuation, research and development analysis; Investment/portfolio managers;
Equity trust/fund managers in researching companies to invest in; Portfolio planners in most financial institutions and investment houses
who need to value companies; Directors of quantitative analysis in corporates, investment banks and venture capitalist houses; Chief
economists in investment houses; Consultants; Actuaries; Risk managers; Regulators and central bankers; MBA graduate students.
Contents
Real R&D option models: classics and development (Paxson); R&D (Dis)investment decisions (Bieke, Klumpes, Tippett); Information uncertainty
and real options (Bellalah); Subsidies for R&D investments (Jou, Lee); A gene to drug venture: Poisson and extreme distribution models;
R&D real American sequential investment options (Lee, Paxson); Implementation uncertainty and investment timing (Tsekrekos); Review of
classical & new real R&D empirical applications (Paxson); Venture capital investments (Seppa, Laamanen); Geological uncertainty (Cortazar,
Casassus, Schwartz); Service sector R&D (Warren, Jensen); Pharmaceutical R&D (Loch, Bode-Greuel); Electronics R&D new product (Lint,
Pennings); Appendix 1: Models in Excel; Appendix 2: Real R&D Options Database;Index.
| Bibliographic details |
Hardbound, 333 pages, publication date: DEC-2002
ISBN-13: 978-0-7506-5332-9
ISBN-10: 0-7506-5332-9
Imprint: BUTTERWORTH HEINEMANN
|
| Price and Ordering |
Price:
GBP 68
EUR 79.95
USD 107
|  |
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
|
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
|
999/999
Last update: 30 Nov 2009
|
|
| |
| | |
|
|
| |
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company